The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multice...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nature medicine Ročník 27; číslo 11; s. 1954 - 1960
Hlavní autori: Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Tang, Fengming, Khariton, Yevgeniy, Malik, Ali O., Khumri, Taiyeb, Umpierrez, Guillermo, Lamba, Sumant, Sharma, Kavita, Khan, Sadiya S., Chandra, Lokesh, Gordon, Robert A., Ryan, John J., Chaudhry, Sunit-Preet, Joseph, Susan M., Chow, Chen H., Kanwar, Manreet K., Pursley, Michael, Siraj, Elias S., Lewis, Gregory D., Clemson, Barry S., Fong, Michael, Kosiborod, Mikhail N.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New York Nature Publishing Group US 01.11.2021
Nature Publishing Group
Predmet:
ISSN:1078-8956, 1546-170X, 1546-170X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.